GN
Genscript Biotech Corporation
GNNSF · OTC
$4.10 +0.00% (+$0.00)
1M +10.81%
Market Cap $8.96B
P/E Ratio -
Div. Yield -
ROE 12.87%
Bulios Fair Price
$2.52
38.5% downside
Current Price
$4.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GNNSF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
22 /100
Expensive P/S 9.32x
P/B 2.26x
P/FCF 37.06x
Growth
91 /100
Growing Book val. growth 57.64%
Rev. growth 15.37%
FCF growth N/A
Profitability
80 /100
Strong Net margin 55.53%
Op. margin 26.60%
FCF margin 25.15%
Quality
16 /100
Poor ROE 12.87%
ROA 11.00%
Asset turnover 0.20x
Debt
91 /100
Low Current ratio 1.47x
Int. coverage 14.76x
Net debt/EBITDA 1.06x
Stability
26 /100
Unstable Rev. volatility 46.58%
EPS volatility 1,810.42%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GNNSF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Weihui Shao
Employees
6,165
Headquarters
Hong Kong
Upcoming events
24 MAR
Earnings
Upcoming earnings report